Pixium Vision reports that follow-up from 18 to 24 months after implantation showed that their PRIMA Bionic Vision System sustainably elicited light perception in all four dry AMD patients with favorable safety profile. Moreover, the second-generation transparent glasses, enabling to combine natural peripheral vision and prosthetic vision, greatly benefited patients and their visual acuity by 3 to 7 lines.
“The Prima System has demonstrated excellent results in improvement of visual acuity in this study and which have not been previously demonstrated in this patient population. A 3-line improvement can mean the difference between recognizing or not recognizing the letters on a street sign, and so these data reinforce the potential to make a significant difference to the lives of patients,” said Dr. Yannick le Mer, the surgeon who implanted the Prima System patients in the study. Dr. le Mer is head of the Vitreo-retinal Unit at Fondation Adolphe de Rothschild Hospital in Paris and a scientific advisor to Pixium Vision.
Based on these positive data the Prima System will be tested in PRIMAvera, the pivotal trial designed to provide the safety and efficacy data required for filing marketing authorization applications in the U.S., Europe and other parts of the world.
To read about all research and developments related to dry AMD, visit A Guide to Research In Dry AMD on this site.